GlassScriptPhysician profile
Jaimee Jones
NPI 1730763988
$890.88
in general payments reported to CMS, 2019-2025
15 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.34 · 2022: $216 · 2023: $191 · 2024: $127 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $159.74 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.05 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $130.42 | 2022-2025 | Farxiga, Airsupra, Lokelma |
| Novartis Pharmaceuticals Corporation | $97.37 | 2023-2025 | |
| Pfizer INC. | $79.59 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.00 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $42.49 | 2025 | |
| Novo Nordisk INC | $32.57 | 2022 | |
| Evoke Pharma, INC. | $32.13 | 2021-2025 | |
| Lilly USA, LLC | $31.26 | 2022-2025 | Mounjaro, Zepbound |
| Agios Pharmaceuticals, INC. | $23.91 | 2025 | Pyrukynd |
| Ferring Pharmaceuticals INC. | $19.30 | 2023 | Euflexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.92 | 2025 | Caplyta |
| Alexion Pharmaceuticals, INC. | $14.96 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.17 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaimee Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.